1. Home
  2. NTRA vs IR Comparison

NTRA vs IR Comparison

Compare NTRA & IR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$187.50

Market Cap

32.9B

Sector

Health Care

ML Signal

HOLD

Logo Ingersoll Rand Inc.

IR

Ingersoll Rand Inc.

HOLD

Current Price

$81.94

Market Cap

33.8B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRA
IR
Founded
2003
1859
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
32.9B
33.8B
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
NTRA
IR
Price
$187.50
$81.94
Analyst Decision
Strong Buy
Buy
Analyst Count
14
7
Target Price
$259.07
$99.86
AVG Volume (30 Days)
1.0M
3.1M
Earning Date
05-19-2026
05-15-2026
Dividend Yield
N/A
0.10%
EPS Growth
0.65
N/A
EPS
N/A
1.45
Revenue
$210,939,000.00
$2,375,400,000.00
Revenue This Year
$16.65
$7.23
Revenue Next Year
$19.22
$4.80
P/E Ratio
N/A
$55.97
Revenue Growth
N/A
22.48
52 Week Low
$125.38
$65.61
52 Week High
$256.36
$100.96

Technical Indicators

Market Signals
Indicator
NTRA
IR
Relative Strength Index (RSI) 33.62 30.64
Support Level $182.20 $78.21
Resistance Level $251.09 $84.66
Average True Range (ATR) 8.09 2.42
MACD -1.01 -1.59
Stochastic Oscillator 7.21 13.95

Price Performance

Historical Comparison
NTRA
IR

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About IR Ingersoll Rand Inc.

Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.7 billion in revenue in 2025.

Share on Social Networks: